SEC Company Response from enVVeno Medical (NVNO) — Jun 10, 2019

enVVeno Medical Corp
Date: June 10, 2019 · CIK: 0001661053 · Accession: 0001493152-19-008923

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-232035

Date

June 10, 2019

Author

Chief

Form

CORRESP

Company

enVVeno Medical Corp

Letter

VIA EDGAR Office of Financial Services Re: Hancock Jaffe Laboratories, Inc. Registration Statement on Form S-1 Filed June 7, 2019 File No. 333-232035

Dear Mr. Jones:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Hancock Jaffe Laboratories, Inc., hereby requests acceleration of effectiveness of the above referenced Registration Statement so that it will become effective at 5:00 p.m. EST on Tuesday, June 11, 2019, or as soon as thereafter practicable.

Very
truly yours,
/s/
Robert A. Berman

Show Raw Text

CORRESP
1
filename1.htm

HANCOCK
JAFFE LABORATORIES, INC.

70
Doppler

Irvine,
California 92618

June
10, 2019

VIA
EDGAR

U.S.
Securities and Exchange Commission

Office
of Financial Services

100
F Street, N.E.

Mail
Stop 4628

Washington,
DC 20549

Attn:
Tom Jones

    Re:
    Hancock
    Jaffe Laboratories, Inc.

    Registration
    Statement on Form S-1

    Filed
    June 7, 2019

    File
    No. 333-232035

Dear
Mr. Jones:

Pursuant
to Rule 461 under the Securities Act of 1933, as amended, Hancock Jaffe Laboratories, Inc., hereby requests acceleration of effectiveness
of the above referenced Registration Statement so that it will become effective at 5:00 p.m. EST on Tuesday, June 11, 2019, or
as soon as thereafter practicable.

    Very
    truly yours,

    /s/
    Robert A. Berman

    Robert
    A. Berman

    Chief
    Executive Officer

    cc:
    Ellenoff
    Grossman & Schole LLP

SecProbe.io